Reoperative surgery for early- and late-onset prosthetic valve endocarditis: temporal trends and outcomes

早期和晚期人工瓣膜心内膜炎的再次手术:时间趋势和结果

阅读:1

Abstract

OBJECTIVES: Prosthetic valve endocarditis (PVE) remains a serious complication following aortic valve replacement, with varying outcomes based on timing of presentation. This study investigated the relationship between timing of reoperation and outcomes in PVE patients using a nationwide database, while examining temporal trends and identifying mortality risk factors. METHODS: We analysed 406 patients who underwent reoperative surgery for PVE between 1996 and 2019 across the United Kingdom using the National Institute of Cardiovascular Outcomes Research database. Patients were categorized into early (≤1 year, n = 131) and late (>1 year, n = 275) reoperation groups. Propensity score matching was performed to compare outcomes, and multivariable analysis identified mortality predictors. RESULTS: The overall incidence of reoperative surgery for PVE increased over the study period, while the proportion of early-onset PVE decreased from 85.7% in 1998 to 20% in 2019. In matched groups (113 pairs), early reoperation cases required longer cardiopulmonary bypass (135 vs 122 min, P = 0.005) and cross-clamp times (95 vs 88 min, P = 0.011), with extended hospital stays (18.5 vs 14.0 days, P = 0.006). Overall mortality was 8.4%, with an early mortality of 10.8% opposed to 6.2% in late cases (P = 0.338; Lasso AUC: 0.746). Age emerged as the strongest predictor of mortality (OR: 1.14, 95% CI: 1.05-1.27, P = 0.0). CONCLUSIONS: This nationwide analysis demonstrates improved PVE outcomes compared to historical data, with overall mortality of 8.4%. While early reoperations were associated with more complex procedures and longer hospital stays, mortality rates were statistically similar. Age remains the primary determinant of mortality risk.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。